Prognostic Significance of Bioscore in Nonmetastatic Breast Cancer

NCT03638219 | Completed DMC

• 1 other identifier: Bioscore in breast cancer
• Study Type: observational
• Target: 317
• Locations: 1 country
• Sites: 1

Brief Summary

assess the validity of applying the bioscore system to predict the disease-free survival (The percentage of people in a study or treatment group who have not experienced disease relapse in a defined period of time.) in breast cancer patients presenting to our

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• the correlation between pathological stage, T stage (T), nodal stage (N), grade (G), estrogen receptor (ER) status (E) and human epidermal growth factor receptor (HER2) status combined score and the disease specific survival (DSS)

  Disease free survial:The percentage of people in a study or treatment group who have not experienced disease relapse in a defined period of time. The time period usually begins after surgerical treatment and ends at the end of study period 2020

  Non metastatic breast cancer patients presented at our department from 2015 to 2018.. Then follow up till 2020

Interventions

Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020. OTHER

Data collection, follow up and bioscore calculation at the end of study

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Breast cancer in female patients only.
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

non metastatic breast cancer patients presenting to our department during period of our study.

You may qualify if:

• \- Female patients Newly diagnosed breast cancer patients presented to clinical oncology department, Assiut University in the period between (2015\_2018).
• Histologically confirmed invasive breast carcinoma (IBC) Age: ≥18 and older Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Complete medical records and follow up

You may not qualify if:

• Male patients No definitive surgery Incomplete medical records or follow-up status Unavailability of hormonal receptor status Carcinoma in situ or other rare tumors of the breast as phylloides tumors, pregnancy and lactation

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University hospital

Asyut, Egypt

Location

Related Publications (2)

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.

  PMID: 25220842 BACKGROUND

• Mohamed RF, Abdelhameed DH, Mohamed MA. Combination of Anatomical and Biological Factors to Predict Disease-Free Survival in Breast Cancer. JCO Glob Oncol. 2023 Mar;9:e2200269. doi: 10.1200/GO.22.00269.

  PMID: 36888928 DERIVED

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle invistigator

Study Record Dates

• First Submitted: August 16, 2018
• First Posted: August 20, 2018
• Study Start: January 1, 2018
• Primary Completion: September 30, 2020
• Study Completion: October 16, 2020
• Last Updated: March 18, 2021

Record last verified: 2021-03

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)